에 대한 최신 뉴스 Avid Bioservices (NASDAQ:CDMO) 주식

Avid Bioservices

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CDMO

UPWK

목요일(7일) 아침, 미국 주식 선물이 상승세를 보인 가운데, 오늘 투자자들의 관심을 끌 만한 종목은 다음과 같다. 

목요일 주목해야 할 주식: 허쉬, 업워크, 할리버튼, 애비드 바이오서비스 및 블록

Avid Bioservices Inc

Biotech

Guidance

Health Care

General

NTLA

Intellia Ended The Third Quarter Of 2024 With Approximately $944.7M In Cash, Cash Equivalents And Marketable Securities, The Cash Position Is Expected To Fund Operations Into Late 2026

Altimmune Announces Completion Of End-of-Phase 2 Meeting With FDA For Pemvidutide In Obesity Treatment; Company And Agency Aligned On Key Efficacy And Safety Measures To Be Studied In Phase 3 Program

Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) reported quarterly losses of $(1.34) per share which beat the analyst consensus estimate of $(1.40) by 4.29 percent.

Intellia Therapeutics Q3 2024 GAAP EPS $(1.34) Beats $(1.40) Estimate

UBS analyst Steven Fisher initiates coverage on Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) with a Buy rating and announces Price Target of $349.

Price Target

Initiation

Analyst Ratings

UBS Initiates Coverage On Vulcan Materials with Buy Rating, Announces Price Target of $349

WhiteHorse Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHF#NASDAQ">WHF</a>) reported quarterly earnings of $0.39 per share which missed the analyst consensus estimate of $0.41 by 3.9 percent. This is a 15.27 percent decrease over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $22.851 million which missed the analyst consensus estimate of $23.203 million by 1.52 percent. This is a 2.69 percent decrease over sales of $23.482 million the same period last year.

Earnings Misses

WhiteHorse Finance Q3 2024 Adj. EPS $0.39 Misses $0.41 Estimate, Sales $22.851M Miss $23.203M Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and maintains $27 price target.

Reiteration

ACAD

HC Wainwright & Co. Reiterates Buy on ACADIA Pharmaceuticals, Maintains $27 Price Target

HOUS

Anywhere Real Estate Q3 2024 Adj. EPS $0.06 May Not Compare To $0.29 Estimate, Sales $1.535B Miss $1.624B Estimate

Fourth Quarter and 2024 Outlook
The Company is reaffirming its fiscal year 2024 outlook of 4.5% to 5.5% revenue growth, based on year-to-date performance and current business trends. For the fourth quarter, the Company anticipates continued strong high single digit year-over-year growth in OEM &amp; National revenue, as well as modest growth in Dealer revenue.
Adjusted EBITDA margin outlook for fiscal 2024 remains 28.0% to 30.0%, reflecting disciplined cost management to continue delivering strong operating leverage for the remainder of the year.

CARS

Cars.com Reaffirms FY24 Revenue Outlook 4.5%-5.5% Growth

MTSI

MACOM Sees Q1 Adj. EPS $0.75-$0.81

The earnings results for Clear Channel Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) for Q3 were made public on Thursday, October 31, 2024 at 06:00 AM.
Here's a comprehensive overview of the announcement.
<h3>Earnings</h3>
Clear Channel Outdoor missed estimated earnings by 0.0%, reporting an EPS of $-0.06 versus an estimate of $-0.06.
Revenue was up $32.20 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
During the previous quarter, the company beat on EPS by $0.01, leading to a 3.0% drop share price change the next day.
Here's a look at Clear Channel Outdoor's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.17</td>
<td>0.04</td>
<td>-0.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.06</td>
<td>-0.04</td>
<td>-0.17</td>
<td>0.05</td>
<td>-0.11</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>557.41M</td>
<td>562.37M</td>
<td>478.55M</td>
<td>610.14M</td>
<td>594.92M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>558.99M</td>
<td>558.54M</td>
<td>481.75M</td>
<td>632.11M</td>
<td>526.79M</td>
</tr>
</tbody>
</table>

<h3>Latest Earnings Reports from Competitors</h3>
With Clear Channel Outdoor's earnings data in hand, it's essential to compare its metrics to those of similar companies, including PubMatic, TechTarget, and National CineMedia.
<ul>
<li>The latest earnings announcement from PubMatic on August 08, 2024 exceeded expectations, with an actual EPS of $0.17 compared to the market's estimate of $-0.02, resulting in a 950.0% increase.</li>
<li>The latest earnings announcement from TechTarget on August 08, 2024 exceeded expectations, with an actual EPS of $0.42 compared to the market's estimate of $0.4, resulting in a 5.0% increase.</li>
<li>The latest earnings report from National CineMedia on November 05, 2024 showed a downturn in performance, with results falling short of expectations. Despite the market's EPS estimate of $-0.03, National CineMedia reported an EPS of $-0.04, marking a -33.33% decrease.</li>
</ul>
<h3>Quarterly Analysis: Competitors' Earnings and Stock Performance</h3>
The provided analysis offers insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Date</th>
<th style="text-align: right;">EPS Expected</th>
<th style="text-align: right;">EPS Announced</th>
<th>EPS Change Percent</th>
<th>Stock Price At Close</th>
<th>Stock Price at Next Day Open</th>
<th>Price Change Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>October 31, 2024</td>
<td style="text-align: right;">-0.06</td>
<td style="text-align: right;">-0.06</td>
<td>0.0%</td>
<td>$1.47</td>
<td>$1.48</td>
<td>0.68%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.02</td>
<td style="text-align: right;">0.17</td>
<td>950.0%</td>
<td>$19.6</td>
<td>$13.82</td>
<td>-29.49%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.40</td>
<td style="text-align: right;">0.42</td>
<td>5.0%</td>
<td>$29.02</td>
<td>$28.38</td>
<td>-2.21%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>November 05, 2024</td>
<td style="text-align: right;">-0.03</td>
<td style="text-align: right;">-0.04</td>
<td>-33.33%</td>
<td>$7.3</td>
<td>$7.35</td>
<td>0.68%</td>
</tr>
</tbody>
</table>

<h3>Delving into Peer Revenue Comparison: Estimated vs. Announced</h3>
Below is a comparison of estimated and announced revenue figures for Clear Channel Outdoor's peers. This comparison gives insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Estimated Revenue</th>
<th>Announced Revenue</th>
<th>Revenue Surprise Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>557.41M</td>
<td>558.99M</td>
<td>0.28%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>70.12M</td>
<td>67.27M</td>
<td>-4.07%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>58.08M</td>
<td>58.91M</td>
<td>1.44%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>58.02M</td>
<td>62.40M</td>
<td>7.55%</td>
</tr>
</tbody>
</table>

To track all earnings releases for Clear Channel Outdoor <a href="https://www.benzinga.com/quote/CCO/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Clear Channel Outdoor Q3 Earnings

MACOM Technology Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) reported quarterly earnings of $0.73 per share which met the analyst consensus estimate. The company reported quarterly sales of $200.710 million which beat the analyst consensus estimate of $200.406 million by 0.15 percent. This is a 33.47 percent increase over sales of $150.375 million the same period last year.

Earnings Beats

MACOM Technology Solns Q4 2024 Adj. EPS $0.73, Inline, Sales $200.710M Beat $200.406M Estimate

Turning Point Brands Raised Previous Full-year 2024 Adjusted EBITDA Guidance From $98M-$102M To $101M-$103M, Excluding CDS

THRY

Thryv Holdings See FY24 Adj. EBITDA $33.5M-$34.5M

Thryv Holdings Sees Q4 Adj. EBITDA $9.5M-$10.5M

Seaport Global analyst Aaron Kessler downgrades Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) from Buy to Neutral.

Downgrades

DUOL

Seaport Global Downgrades Duolingo to Neutral

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Denali Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNLI#NASDAQ">DNLI</a>) with a Buy and maintains $90 price target.

DNLI

HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $90 Price Target

Anywhere Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOUS#NYSE">HOUS</a>) reported quarterly sales of $1.53 billion which missed the analyst consensus estimate of $1.62 billion by 5.46 percent. This is a 3.09 percent decrease over sales of $1.58 billion the same period last year.

Anywhere Real Estate Q3 Sales $1.53B Miss $1.62B Estimate

Stock Split

TRNR

Interactive Strength Announces 1-For-100 Reverse Split, Effective November 11

2024 Fourth Quarter Financial Outlook
Management provided an outlook for the fourth quarter, the period ending December 31, 2024. Based on current estimates, management expects:
<ul>
<li>$181 million to $191 million in revenue</li>
<li>$1.51 to $1.70 in diluted GAAP EPS</li>
<li>$1.72 to $1.91 in diluted non-GAAP EPS</li>
</ul>

NVMI

Nova Expects Q4 Revenue Of $181M-$191M Vs $171.84M Est, Adj EPS Of $1.72-$1.91 Vs $1.68 Est

Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) reported quarterly losses of $(2.65) per share which missed the analyst consensus estimate of $(0.95) by 178.95 percent. The company reported quarterly sales of $179.852 million which beat the analyst consensus estimate of $179.230 million by 0.35 percent. This is a 2.16 percent decrease over sales of $183.822 million the same period last year.

Thryv Holdings Q3 2024 GAAP EPS $(2.65) Misses $(0.95) Estimate, Sales $179.852M Beat $179.230M Estimate

An announcement from Avid Bioservices ( ($CDMO) ) is now available. Avid Bioservices, Inc. has reported a strong start to fiscal 2025 with first-qu...

Avid Bioservices Reports Growth and Strong Pipeline

Avid Bioservices, Inc. (CDMO) Q1 2025 Earnings Call Transcript

In a report released yesterday, Sean Dodge from RBC Capital maintained a Buy rating on Avid Bioservices (CDMO – Research Report), with a price targ...

RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)

Avid Bioservices stock rallies 18% after reporting increased backlog

Avidity Biosciences: Good Prospects, But We Are A Little Late

Avid Bioservices ( ($CDMO) ) has shared an update. At Avid Bioservices' 2024 Annual Meeting, stockholders approved significant amendments to the 20...

Avid Bioservices' Strategic Shareholder and Governance Updates

16:55 EST Avid Bioservices (CDMO) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breakin...

Avid Bioservices trading halted, news pending

18:35 EST Avid Bioservices (CDMO) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...

Avid Bioservices trading resumes

Avid Bioservices (CDMO), GHO Capital Partners LLP and Ampersand Capital Partners announced they have entered into a definitive merger agreement for...

GHO Capital / Ampersand Capital to acquire Avid Bioservices for $12.50 per share

RBC Capital downgraded Avid Bioservices (CDMO) to Sector Perform from Outperform with a price target of $12.50, up from $12, after the company anno...

Avid Bioservices downgraded to Sector Perform from Outperform at RBC Capital

HRMY

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avid Bioservices, Inc. - CDMO

Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance

Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024

Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference

Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction

Abivax

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

AnaptysBio

Annexon

Astria Therapeutics

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

Dianthus Therapeutics, Inc. - Common Stock

Dianthus Therapeutics

Exscientia Plc - American Depositary Shares

Exscientia

Humacyte

Immunome

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Mereo BioPharma Group plc - American Depositary Shares

Mereo BioPharma Group

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Opthea Limited - American Depositary Shares

Opthea

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Sana Biotechnology

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Stoke Therapeutics

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Entrada Therapeutics, Inc. - Common Stock

Entrada Therapeutics

Tourmaline Bio

Y-mAbs Therapeutics

RBC Capital

Stephens & Co.

Craig-Hallum

Keybanc

목요일(7일) 아침, 미국 주식 선물이 상승세를 보인 가운데, 오늘 투자자들의 관심을 끌 만한 종목은 다음과 같다.
<ul>
<li>월가에서는 실적 발표를 앞둔 허쉬 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>)의 분기 주당순이익은 2.56달러, 매출운 30억 8천만 달러로 예상하고 있다. <a href="https://pro.benzinga.com/dashboard">벤징가 프로</a> 데이터에 따르면, 허쉬 주가는 장전 시간외거래에서 1.2% 상승한 177.98달러에 거래되고 있다.</li>
<li>업워크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>)의 3분기 재무 실적은 예상치를 상회했고 1억 달러 규모의 자사주매입 프로그램을 발표했다. 또한 업워크는 4분기 매출을 1억 7,800만 달러~1억 8,300만 달러 범위, 조정 주당순이익을 24센트~28센트 범위로 예상했다. 업워크 주가는 장전 시간외거래에서 7% 상승한 15.60달러에 거래되고 있다.</li>
<li>애널리스트들은 실적 발표를 앞둔 할리버튼 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>)의 분기 주당순이익을 75센트, 매출을 58억 3천만 달러로 예상한다. 오늘 개장 전 실적을 발표할 것이다. 장전 시간외거래에서 할리버튼의 주가는 0.3% 상승한 30.60달러에 거래되고 있다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/">프리마켓 커버리지</a>를 확인하세요.
<ul>
<li>애비드 바이오서비스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDMO#NASDAQ">CDMO</a>)는 GHO 캐피털 파트너스와 앰퍼샌드에 11억 달러로 인수되기로 합의했다. 애비드의 주가는 장전 시간외거래에서 11.6% 상승한 12.25달러에 거래되고 있다.</li>
<li>애널리스트들은 곧 실적을 발표하는 블록(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>)의 주당순이익을 87센트, 매출을 62억 4천만 달러로 예상한다. 블록 주가는 장전 시간외거래에서 0.4% 상승한 77.98달러에 거래되고 있다.</li>
</ul>
더 읽기: <a href="https://kr.benzinga.com/news/global/europe/asml-%ED%99%80%EB%94%A9-%ED%8A%B8%EB%9F%BC%ED%94%84-%EB%8B%B9%EC%84%A0-%ED%9B%84-%EC%99%9C-2-%EC%9D%B4%EC%83%81-%ED%95%98%EB%9D%BD%ED%96%88%EC%9D%84%EA%B9%8C/">ASML 홀딩, 트럼프 당선 후 왜 2% 이상 하락했을까?</a>
사진 제공: 허쉬
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Avid Bioservices

뉴스

에 대한 최신 뉴스 Avid Bioservices (NASDAQ:CDMO) 주식

목요일, 11월 07, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌